STOCK TITAN

Ovid Therapeutics (OVID) Stock News

OVID NASDAQ

Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.

Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.

Rhea-AI Summary

Ovid Therapeutics (OVID) reported third-quarter financial results and advanced clinical programs, with cash, cash equivalents and marketable securities of $161.4 million. Ovid expects its financial runway to extend into 2029. Third-quarter net loss widened to $20.780 million from $12.158 million in 2025, while common-stock loss per share narrowed to $0.10 from $0.17.

OV329's Phase 2 focal epilepsy study is enrolling, with completion expected in H2 2027; photosensitivity study results are expected in Q1 2027. A study in tuberous sclerosis complex-associated seizures is planned before year-end 2026. OV4071's Phase 1 study has reported no serious adverse events to date. Its results and those from a planned ketamine challenge study are expected in Q1 2027. Previously assigned soticlestat rights could generate up to $294.5 million in milestones, partly payable to Ligand, plus potential royalties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) announced that its management will participate in three investor conferences on November 10, 11 and 16, 2026.

Presentations are scheduled for Guggenheim at 8:30 am ET, Stifel at 3:20 pm ET and UBS European Healthcare at 2:40 pm GMT, respectively. Webcasts will be accessible through the company’s investor website, with replays available for approximately 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
conferences
-
Rhea-AI Summary

Actinium Pharmaceuticals (NYSE American: ATNM) appointed Matt David, M.D., as Chief Financial Officer to lead its finance and capital markets functions. He will also oversee accounting and investor relations and serve as principal financial officer.

David joins from CorMedix, where he most recently served as Executive Vice President and Chief Business Officer after joining as Chief Financial Officer in 2020. His experience spans more than two decades across biopharmaceutical operating leadership, healthcare investment banking and equity research. Before CorMedix, he served as Head of Strategy at Ovid Therapeutics. His banking experience includes advising biopharmaceutical companies on financings and transactions. The appointment comes with Actinium's first-in-human study of ATNM-400 underway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.20%
Tags
none
Rhea-AI Summary

Ovid Therapeutics (OVID) will participate in two upcoming investor conferences in September 2026. Management will present at the Cantor Global Healthcare Conference on September 9 at 2:10 pm ET and at the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 11:30 am ET. Webcasts and 30-day replays will be available via the Events & Presentations section of the company’s investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) reported second quarter 2026 results and major pipeline and corporate developments. Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026, and the company expects its financial runway to extend into 2029.

Ovid is advancing OV4071, a first-ever oral direct KCC2 activator, in an ongoing Phase 1 study, with a ketamine challenge study planned for the second half of 2026 and Phase 2 proof-of-concept in acute schizophrenia targeted for 2027. The company also initiated Phase 2 and photosensitivity proof-of-concept studies for OV329, a next-generation GABA-AT inhibitor, across multiple seizure disorders.

A new Perceptive Advisors–backed company acquired global rights to soticlestat; Ovid obtained equity in the new company and is eligible for up to $294.5 million in potential milestones plus low- to mid-single digit royalties. Second quarter 2026 revenue was $0.7 million versus $6.3 million a year earlier, with net loss widening to $15.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) announced several senior leadership changes to support its next phase of development. Kevin Norrett will join as Chief Business Officer, Charles Carter is promoted to Chief Financial Officer, and former CFO Jeffrey Rona will remain an advisor through 2027.

Eliseo Salinas becomes Executive R&D Advisor, and Victoria Fort is promoted to Chief Strategy Officer. According to Ovid Therapeutics, Fort previously led two financings that extended the company’s cash runway into 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) announced that management will participate in two June 2026 investor conferences focused on neurology.

Events include the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 p.m. and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15, with live and archived webcasts via its investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
conferences
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) appointed physician-scientist and biotech entrepreneur Anna Greka, M.D., Ph.D. to its Board of Directors, effective June 15, 2026. She will Chair the new Science and Technology Committee and join the Compensation Committee.

Greka leads Ladders to Cures, is a Core Institute Member and executive leader at the Broad Institute, and Professor of Medicine at Harvard Medical School and Mass General Brigham. She has founded and advised multiple biotech companies, including ventures whose assets were acquired by Bristol Myers Squibb and AstraZeneca.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
management
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) reported Q1 2026 business and financial updates, highlighting pipeline progress and strengthened capital.

OV329 showed favorable safety up to 9 mg and is moving into Phase 2 studies in treatment‑resistant epilepsies and new pediatric programs. OV4071, an oral KCC2 activator, began Phase 1 dosing. Recent PIPE financings and warrant exercises raised about $113.9 million, bringing cash and securities to $165.6 million on March 31, 2026 and extending projected runway into 2029. Q1 net loss was $17.0 million on operating expenses of $17.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) will host a KCC2 Deep Dive R&D event on Tuesday, April 14, 2026 at 9:30 am ET in New York, with a simultaneous webcast. The session will review Ovid's first-in-class KCC2 portfolio, pharmacodynamic data, translational and clinical strategy, and market potential.

Speakers include CEO Meg Alexander, independent clinicians, translational experts, and leading neuroscientists; a webcast replay will be archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none

FAQ

What is the current stock price of Ovid Therapeutics (OVID)?

Ovid Therapeutics (OVID) last closed at $2.22.

What is the market cap of Ovid Therapeutics (OVID)?

The market cap of Ovid Therapeutics (OVID) is approximately $419.0M.